Navigation Links
Synthetic derivatives of THC may weaken HIV-1 infection to enhance antiviral therapies
Date:4/30/2013

A new use for compounds related in composition to the active ingredient in marijuana may be on the horizon: a new research report published in the Journal of Leukocyte Biology shows that compounds that stimulate the cannabinoid type 2 (CB2) receptor in white blood cells, specifically macrophages, appear to weaken HIV-1 infection. The CB2 receptor is the molecular link through which the pharmaceutical properties of cannabis are manifested. Diminishing HIV-1 infection in this manner might make current anti-viral therapies more effective and provide some protection against certain HIV-1 complications.

"The synthetic compounds we used in our study may show promise in helping the body fight HIV-1 infection,'" said Yuri Persidsky, M.D., Ph.D., a researcher involved in the work from the Department of Pathology and Laboratory Medicine at Temple University School of Medicine in Philadelphia, PA. "As compounds like these are improved further and made widely available, we will continue to explore their potential to fight other viral diseases that are notoriously difficult to treat."

To make this discovery, scientists used a cell culture model to infect human macrophages with HIV-1 and added synthetic compounds similar to the active ingredient in marijuana to activate the CB2 receptor. At different times during the infection, samples from the culture were taken to see if the replication of the HIV virus was decreased. The researchers observed diminished HIV growth and a possible protective effect from some HIV-1 complications.

"HIV/AIDS has posed one of the most significant health challenges in modern medicine," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "Recent high profile vaccine failures mean that all options need to be on the table to prevent or treat this devastating infection. Research on the role of cannabinoid type 2 receptors and viral infection may one day allow targeting these receptors to be part of combination therapies that use exploit multiple weaknesses of the virus simultaneously."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Predictability: The brass ring for synthetic biology
2. Synthetic molecule first electricity-making catalyst to use iron to split hydrogen gas
3. Synthetic Biologics to Present at the 2013 BIO CEO & Investor Conference
4. Developing microbial cell factories by employing synthetic small regulatory RNAs
5. Oscillating gel gives synthetic materials the ability to speak
6. Synthetic and biological nanoparticles combined to produce new metamaterials
7. New report finds increase in media coverage of synthetic biology
8. Synthetic fuel could eliminate US need for crude oil
9. Microchoreography: Researchers use synthetic molecule to guide cellular dance
10. Nottingham part of £20m investment for UK synthetic biology
11. Synthetic biofilter wins through to the top Sweet 16 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... Jan. 19, 2017 /PRNewswire -- WuXi AppTec, a ... capability and technology platform, today announced that it ... focused preclinical drug discovery contract research organization (CRO). ... a wholly-owned subsidiary of WuXi, and will continue ... providing greater services. The acquisition will further strengthen ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  ArmaGen, ... Mathias Schmidt , Ph.D., as chief executive officer, ... of directors. Dr. Schmidt brings to ArmaGen more than ... the research and development of biotherapeutics and pharmaceuticals. ... executive with the diverse experience and skillset necessary ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology: